Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.